# EDGAR Filing Document

**Accession Number:** 0001535955
**File Stem:** 0001493152-26-008201
**Filing Date:** 2026-2
**Character Count:** 3158
**Document Hash:** 4b63acfb03b7d0d1f3cda0d5b88af9bd
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-008201.hdr.sgml**: 20260226

**ACCESSION NUMBER**: 0001493152-26-008201

**CONFORMED SUBMISSION TYPE**: 424B5

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260226

**DATE AS OF CHANGE**: 20260226

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Lipocine Inc.
- **CENTRAL INDEX KEY:** 0001535955
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 990370688
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 424B5
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-275716
- **FILM NUMBER:** 26690709

**BUSINESS ADDRESS:**
- **STREET 1:** 675 ARAPEEN DRIVE, SUITE 202
- **CITY:** SALT LAKE CITY
- **STATE:** X1
- **ZIP:** 84108
- **BUSINESS PHONE:** 801 994 7383

**MAIL ADDRESS:**
- **STREET 1:** 675 ARAPEEN DRIVE, SUITE 202
- **CITY:** SALT LAKE CITY
- **STATE:** X1
- **ZIP:** 84108

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MARATHON BAR CORP
- **DATE OF NAME CHANGE:** 20111130

**Filed Pursuant to Rule 424(b)(5)**

**Registration No. 333-275716**

**Prospectus Supplement**

**(To Prospectus Dated April 25, 2024)**

![](form424b5_001.jpg)

**Up to $50,000,000**

**of**

**Common Stock**

This prospectus supplement amends and supplements the information in the prospectus supplement, dated April 26, 2024, filed as a part of our registration statement on Form S-3 (File No. 333-275716) (the "Prior Prospectus"). This prospectus supplement should be read in conjunction with the Prior Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prior Prospectus. This prospectus supplement is not complete without and may only be delivered or utilized in connection with, the Prior Prospectus, and any future amendments or supplements thereto.

Under the Prior Prospectus, we registered up to an aggregate of $10,616,169 of our common stock, $0.0001 par value per share, for offer and sale pursuant to a sales agreement, dated April 26, 2024, (the "Sales Agreement"), between us and A.G.P./Alliance Global Partners. From April 26, 2024 through the date of this prospectus supplement, we sold an aggregate of 1,603,431 shares of our common stock, for an aggregate purchase price of $10,615,576 under the Prior Prospectus. As of the date of this prospectus supplement, we are increasing the aggregate amount of common stock that we are offering pursuant to the Sales Agreement, such that we are offering up to an aggregate of $50,000,000 of our common stock for sale under the Sales Agreement, including the shares of common stock previously sold, or $39,384,424 from and after the date hereof.

**Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.**

**A.G.P.**

**The date of this prospectus supplement is February 26, 2026.**